Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for proteinuria in type 2 diabetes mellitus
ACTRN12624000033549Phase 4Not yet recruiting
- Sponsor
- Lady Reading Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM), proteinuria and chronic kidney disease (CKD) (2 arms), sponsored by Lady Reading Hospital. Primary endpoint: 24-hour urinary protein. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)proteinuriachronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12624000033549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000033549.